Syndax Capex To Revenue from 2010 to 2024

SNDX Stock  USD 13.93  0.46  3.41%   
Syndax Pharmaceuticals Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue will likely drop to 0 in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.001062
Current Value
0.001009
Quarterly Volatility
0.06026126
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Syndax Pharmaceuticals over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Syndax Pharmaceuticals' Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Syndax Capex To Revenue Regression Statistics

Arithmetic Mean0.06
Geometric Mean0.01
Coefficient Of Variation106.13
Mean Deviation0.05
Median0.08
Standard Deviation0.06
Sample Variance0
Range0.213
R-Value(0.58)
Mean Square Error0
R-Squared0.33
Significance0.02
Slope(0.01)
Total Sum of Squares0.05

Syndax Capex To Revenue History

2024 0.001009
2023 0.001062
2019 9.23E-4
2018 0.12
2017 0.0398
2016 0.21

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.